pyrazines has been researched along with chalcone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amerik, AY; Issaenko, OA | 1 |
| Chen, S; Huang, J; Huang, Q; Li, Y; Luo, Y; Wang, C; Wu, W; Yu, L; Zha, D; Zhang, C; Zhang, J; Zhou, W | 1 |
2 other study(ies) available for pyrazines and chalcone
| Article | Year |
|---|---|
Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes.
Topics: Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Boronic Acids; Bortezomib; Breast Neoplasms; Catalytic Domain; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Chalcone; Cyclin D1; Cysteine; Dose-Response Relationship, Drug; Endopeptidases; Female; HeLa Cells; Humans; Ovarian Neoplasms; Phenotype; Piperidones; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53; Ubiquitin Thiolesterase; Ubiquitins | 2012 |
Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chalcone; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Pyrazines; Structure-Activity Relationship; Triple Negative Breast Neoplasms | 2021 |